Details of the Drug

General Information of Drug (ID: DMEZ2KH)

• Drug Name: Ocrelizumab
• Synonyms: Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Approved	[1]
Multiple sclerosis	8A40	Approved	[2]

• Drug Type: Antibody
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3,510 mgday/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 212 mg/L [3]
  Clearance: The clearance of drug is 0.17 L/day [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 26 days [3]
  Vd: The volume of distribution (Vd) of drug is 2.78 L [4]
• Cross-matching ID:
  DrugBank ID: DB11988
  TTD ID: D0YV4F

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[5], [6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Diffuse large B-cell lymphoma
• ICD Disease Classification: 2A81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Leukocyte surface antigen Leu-16 (CD20)	DTT	MS4A1	4.00E-02	0.25	0.56

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ocrelizumab

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Ocrelizumab and Siponimod.	Multiple sclerosis [8A40]	[15]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Ocrelizumab and Ozanimod.	Multiple sclerosis [8A40]	[16]

Coadministration of a Drug Treating the Disease Different from Ocrelizumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
LY2835219	DM93VBZ	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and LY2835219.	Breast cancer [2C60-2C6Y]	[17]
Polatuzumab vedotin	DMF6Y0L	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[17]
Lisocabtagene maraleucel	DMP45ME	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Lisocabtagene maraleucel.	Diffuse large B-cell lymphoma [2A81]	[17]
Axicabtagene ciloleucel	DMYHN59	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Axicabtagene ciloleucel.	Diffuse large B-cell lymphoma [2A81]	[17]
Bay 80-6946	DMLOS5R	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Bay 80-6946.	Follicular lymphoma [2A80]	[17]
Avapritinib	DMK2GZX	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[17]
177Lu-DOTATATE	DMT8GVU	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[17]
Brigatinib	DM7W94S	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Brigatinib.	Lung cancer [2C25]	[17]
Lurbinectedin	DMEFRTZ	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Lurbinectedin.	Lung cancer [2C25]	[17]
Belantamab mafodotin	DMBT3AI	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Belantamab mafodotin.	Multiple myeloma [2A83]	[17]
Inebilizumab	DMI0RHA	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Inebilizumab.	Nervous system paraneoplastic/autoimmune disorder [8E4A]	[17]
Tildrakizumab	DMLW9HG	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Tildrakizumab.	Psoriasis [EA90]	[17]
Risankizumab	DMM32GT	Moderate	Additive immunosuppressive effects by the combination of Ocrelizumab and Risankizumab.	Psoriasis [EA90]	[17]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [5] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [6] Clinical pipeline report, company report or official report of Roche (2009).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [9] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [11] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [12] Clinical pipeline report, company report or official report of Genentech (2009).
• [13] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [14] Clinical pipeline report, company report or official report of Genmab.
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.